Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 0.77 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.77 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361367 | 0.98 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNB4CHRNA3MEN1 | |
| SCHEMBL30665760 | 0.98 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNB4CHRNA3MEN1 | |
| SCHEMBL2067959 | 0.96 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNB4CHRNA3MEN1 | |
| SCHEMBL30665753 | 0.96 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNB4CHRNA3MEN1 | |
| SCHEMBL5654646 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL3067510 | 0.84 | CHRNB2 (0.94) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL3067811 | 0.82 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL3707068 | 0.82 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3MEN1 | |
| SCHEMBL30066253 | 0.82 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL2257074 | 0.82 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582422-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
| WO-2024056099-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京华益健康药物研究中心 | 2024-03-21 | — | — | WO | disclosed |
| CN-117720533-A | MetTL3 inhibitor compound and pharmaceutical composition and application thereof | 北京华益健康药物研究中心 | 2024-03-19 | — | — | CN | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| WO-2011075559-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075559-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2011-06-23 | — | — | WO | disclosed |
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007084451-A1 | HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | CHRNB2 4448/4885CHRNA4 4365/4885CHRNB4 4612/4885 |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | CHRNB2 4241/4885CHRNA4 4396/4885CHRNB4 4445/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | CHRNB2 4448/4885CHRNA4 4365/4885CHRNB4 4612/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | CHRNB2 4241/4885CHRNA4 4396/4885CHRNB4 4445/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CHRNB2 1703/4885CHRNA4 2400/4885CHRNB4 2651/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | CHRNB2 4448/4885CHRNA4 4365/4885CHRNB4 4612/4885 |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | METTL3, METTL14, METTL16 | CHRNB2 4468/4885CHRNA4 4400/4885CHRNB4 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.